Literature DB >> 1969453

Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma.

J S Andrews1, A E Berger, C F Ware.   

Abstract

TNF-alpha and lymphotoxin (LT or TNF-beta) are structurally related cytokines that share several proinflammatory and immunomodulatory activities. The shared biologic activities of TNF and LT have been attributed to their binding to a common cell surface receptor(s). We observed that rTNF enhanced the expression of MHC class I proteins on the human T cell hybridoma, II-23.D7, however LT was largely unable to regulate MHC expression. To determine the molecular basis of this disparity between LT and TNF the receptor binding characteristics of rTNF and rLT were investigated by direct and competitive radioligand assays on the II-23.D7 T hybridoma, and for comparison, anti-CD3 activated human T lymphocytes. Specific 125I-rTNF binding to the II-23.D7 line revealed a single class of sites with a Kd = 175 pM and 3000 sites/cell; anti-CD3 activated T cells exhibited specific TNF binding with similar properties. The relationship of receptor occupancy to the induction of MHC class I Ag yielded a hyperbolic curve indicating a complex relationship between rTNF binding and biologic response. LT appeared to function like a partial agonist in that rLT was 10- to 20-fold less effective than rTNF in competitively inhibiting 125I-rTNF binding on the II-23.D7 line. Scatchard type analysis revealed a single class of low affinity binding sites for 125I-rLT. No differences in the competitive binding activity of rTNF and rLT were observed on the anti-CD3-activated T cells. Receptors for rTNF and rLT were immunoprecipitated from the II-23.D7 and activated T cells with anticytokine antibodies after cross-linking of radioiodinated rTNF or rLT to intact cells by using chemical cross-linking reagents. Analysis of the cross-linked adducts by SDS-PAGE and autoradiography indicated a major adduct of 92 kDa for rTNF and 104 kDa for rLT. Enzymatic digestion with neuraminidase or V8 protease revealed a unique structure to these adducts consistent with the cross-linking of a single chain of cytokine to a cell surface glycoprotein. rTNF inhibited the formation of the 104-kDa adduct formed with 125I-rLT on the II-23.D7 line, indicating these two cytokines bind to the same receptor of approximately 80 kDa. These results suggest that the disparate activities of LT and TNF to induce MHC class I proteins on the II-23.D7 cells are, in part, associated with a modified state of a common receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969453

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Tumour necrosis factor-alpha stimulates invasiveness of T-cell hybridomas and cytotoxic T-cell clones by a pertussis toxin-insensitive mechanism.

Authors:  G La Rivière; J W Klein Gebbinck; C A Schipper; E Roos
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

2.  Immune-enhancing effects of gamma-irradiated sericin.

Authors:  In-Bong Song; Hye-Ju Han; Jungkee Kwon
Journal:  Food Sci Biotechnol       Date:  2020-02-10       Impact factor: 2.391

Review 3.  TNF activity and T cells.

Authors:  Amit K Mehta; Donald T Gracias; Michael Croft
Journal:  Cytokine       Date:  2016-08-13       Impact factor: 3.861

4.  The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor.

Authors:  M Grell; H Wajant; G Zimmermann; P Scheurich
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

5.  Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF.

Authors:  A P Cope; D Aderka; D Wallach; M Kahan; N R Chu; F M Brennan; M Feldmann
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

6.  Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis.

Authors:  T M Horton; T S Ranheim; L Aquino; D I Kusher; S K Saha; C F Ware; W S Wold; L R Gooding
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

Review 7.  The role of tumor necrosis factor receptors in cell signaling and the significance of soluble form levels in the serum.

Authors:  Y Abe; Y Watanabe; S Kimura
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

8.  Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.

Authors:  Alexandra Garancher; Hiromichi Suzuki; Svasti Haricharan; Lianne Q Chau; Meher Beigi Masihi; Jessica M Rusert; Paula S Norris; Florent Carrette; Megan M Romero; Sorana A Morrissy; Patryk Skowron; Florence M G Cavalli; Hamza Farooq; Vijay Ramaswamy; Steven J M Jones; Richard A Moore; Andrew J Mungall; Yussanne Ma; Nina Thiessen; Yisu Li; Alaide Morcavallo; Lin Qi; Mari Kogiso; Yuchen Du; Patricia Baxter; Jacob J Henderson; John R Crawford; Michael L Levy; James M Olson; Yoon-Jae Cho; Aniruddha J Deshpande; Xiao-Nan Li; Louis Chesler; Marco A Marra; Harald Wajant; Oren J Becher; Linda M Bradley; Carl F Ware; Michael D Taylor; Robert J Wechsler-Reya
Journal:  Nat Neurosci       Date:  2020-05-18       Impact factor: 24.884

9.  Tumour growth inhibition in mice by glycosylated recombinant human lymphotoxin: analysis of tumour-regional mononuclear cells involved with its action.

Authors:  I Funahashi; H Watanabe; T Abo; K Indo; H Miyaji
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

10.  Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; C Enthammer; M Cassatella; D Nitti; M Lise; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.